Skip to main content

Cyclo Therapeutics, Inc. (CYTH)

NASDAQ: CYTH · Delayed Price · USD
6.60
-0.04 (-0.53%)
After-hours:Oct 21, 2021 7:52 PM EDT
6.64
-0.19 (-2.71%)
At close: Oct 21, 4:00 PM
Market Cap43.14M
Revenue (ttm)964,771
Net Income (ttm)-11.75M
Shares Out6.37M
EPS (ttm)-3.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16,827
Open6.68
Previous Close6.82
Day's Range6.60 - 6.87
52-Week Range3.55 - 17.75
Beta-0.89
AnalystsBuy
Price Target16.00 (+141.1%)
Est. Earnings DateNov 8, 2021

About CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Th...

IndustryDrug Manufacturers-Specialty & Generic
Founded1990
Employees8
Stock ExchangeNASDAQ
Ticker SymbolCYTH
Full Company Profile

Financial Performance

In 2020, CYTH's revenue was $903,376, a decrease of -10.31% compared to the previous year's $1.01 million. Losses were -$8.94 million, 18.7% more than in 2019.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CYTH stock is "Buy" and the 12-month stock price forecast is 16.00.

Price Target
$16.00
(141.15% upside)
Analyst Consensus: Buy

News

Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Suppor...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for pat...

2 days ago - Business Wire

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the 14th International Congress of Inborn E...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

4 days ago - Business Wire

Cyclo Therapeutics to Participate in the 2021 Virtual Cyclodextrin Conference Hosted by CycloLab

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 weeks ago - Business Wire

Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

3 weeks ago - Business Wire

Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

1 month ago - Business Wire

Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

1 month ago - Business Wire

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder

Cyclo Therapeutics Inc (NASDAQ: CYTH) has announced new data from its Phase 1 extension study evaluating Trappsol Cyclo Niemann-Pick Disease Type C1 (NPC), a genetic disorder characterized by the abnorm...

2 months ago - Benzinga

Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foun...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

4 months ago - Business Wire

Cyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol Cyclo

Cyclo Therapeutics Inc (NASDAQ: CYTH) has commenced its pivotal Phase 3 study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study has the regulatory ...

4 months ago - Benzinga

Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ ...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

4 months ago - Business Wire

Cyclo Therapeutics Announces Launch of New Website

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

4 months ago - Business Wire

Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

4 months ago - Business Wire

Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

4 months ago - Business Wire

Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer's Disease Panel

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

5 months ago - Business Wire

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

5 months ago - Business Wire

Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

5 months ago - Business Wire

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

5 months ago - Business Wire

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer's Dis...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

6 months ago - Business Wire

7 Beaten Down Stocks with Significant Insider Buying

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

6 months ago - InvestorPlace

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disea...

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

6 months ago - Business Wire

Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

7 months ago - Business Wire

Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

7 months ago - Business Wire